Searched for
RANBAXY LABORATORIES INDIA
Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...- Ranbaxy ends last trading day on bright note; surges over 5%Sun Pharmaceutical Industries also rose by 5.51 per cent to settle at Rs 1,078.55. The stock was the top gainer among the 30-Sensex scrips.
- Sun Pharma gets RBI nod for transfer of Ranbaxy's overseas investmentsThe central bank also approved issue of equity shares of Sun Pharma to the non-resident holders of equity shares of Ranbaxy Laboratories, t...
- Minority shareholders approval not needed for Sun deal: RanbaxyOn April 7, Sun Pharmaceutical announced it will fully acquire the troubled Ranbaxy Laboratories in an all-stock transaction with a total e...
- Ranbaxy Laboratories recalls 29,790 packs of anti-allergy drug in USRanbaxy Laboratories is recalling 29,790 blister packs of anti-allergy drug in the US, manufactured by its arm Ohms Laboratories, due to de...
- Ranbaxy's US unit gets USFDA's establishment inspection reportThe US health regulator has given Ranbaxy Laboratories' American arm Ohm Laboratories Inc a report indicating closure of inspection of its ...
- Resolved the matter with Ranbaxy: Apollo PharmacyApollo Pharmacy today said it has resolved the matter and will continue to sell Ranbaxy's medicines from its outlets across the country.
- Ranbaxy to launch country's first 'made in India' drugThe antimalaria drug, a combination of two molecules -- arterolane maleate and piperaquine phosphatethe -- is expected to be priced at a si...
- Almost four years after Daiichi Sankyo's acquisition, Ranbaxy back on track with low-cost version of LipitorRanbaxy has started exporting a low-cost version of cholesterol-lowering blockbuster Lipitor to the US from its new facility in Mohali in P...
- Ranbaxy labs gets Health Canada nod for cholesterol lowering drugRanbaxy Labs said it has received approval from the Health Canada to manufacture & mkt its generic RAN-Rosuvastatin tablets used for loweri...
- Ranbaxy signs consent decree with FDA, may pay upto $500 million penaltyRanbaxy has signed a consent decree with the US FD and has set aside a $500 million for penalty which will allow the Indian drug maker to r...
- Ranbaxy's Lipitor copy fate next weekA US court will decide next week if Ranbaxy can launch its low-priced version of the world's best selling drug Lipitor in the American mark...
- Ranbaxy profit triples to Rs 312 croreRanbaxy Laboratories, saw quarterly net profit almost triple but uncertainty over its problems with the US drug regulator and high contribu...
- Ranbaxy launches cholesterol drug in SAfricaRanbaxy Laboratories, India's largest drugmaker by sales, said on Tuesday its unit had launched atorvastatin, generic form of Pfizer Inc's ...
- Ranbaxy to sell stakes in ex-group cosDaiichi Sankyo-controlled Ranbaxy Laboratories plans to divest its investments made by the previous management under Malvinder Mohan Singh ...
- Ranbaxy inks two deals with group firmsRanbaxy Laboratories has sold some land and building for Rs 90 crore to a group company, sources said.
- Ranbaxy can't pop Orchid easilySolrex will have to fork out an extra Rs 400-500 crore to buy a further 20% stake in case it comes with an open offer.
- Setback for Ranbaxy in Lipitor fightIt means that Ranbaxy cannot launch the drug until July, 2010 but it may seek a review of the decision by the Supreme Court of Canada. Biz ...
- Ranbaxy settles generic sale dispute with GSKRanbaxy Laboratories has reached an out-of-court settlement with UK’s pharma major GlaxoSmithKline to market generic copies of the latter’s...
- Ranbaxy gets USFDA nod for diabetic drugDrug maker Ranbaxy's wholly-owned US subsidiary receives USFDA approval to market Metformin Hydrochloride tablets.
Load More
